Benzinga
Benzinga
Benzinga
lunedì, settembre 21

Abbott Laboratories

ABTNYSE
Trade with Public
Trade with Public
$102.61
0.380.37%
In chiusura: Sep 18, 5:00 PM EST
$102.61
N/A
Post-mercato: Sep 18, 4:13 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Abbott Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Abbott Laboratories (ABT).

Price Target Range — 8 Quarters

Analyst Consensus — 22 Analysts

21Buy
1Hold
Consensus RatingBuy# Analysts22Avg. Consensus PT$129Upside to Avg. PT+26.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 8, 2026TD CowenJoshua JenningsMaintainedBuy$135
Aug 21, 2026TD CowenJoshua JenningsPT RaiseBuy$115→$135
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $135 Price Target

TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $135 price target.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price Target

Wolfe Research analyst Mike Polark upgrades Abbott Laboratories (NYSE:ABT) from Peer Perform to Outperform and announces $130 price target.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $125.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises the price target from $108 to $112.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $115 to $118.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $110 to $120.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved